United Therapeutics (NASDAQ:UTHR) CFO Sells $10,079,790.00 in Stock

United Therapeutics Corporation (NASDAQ:UTHR) CFO James Edgemond sold 21,000 shares of the company’s stock in a transaction that occurred on Monday, December 1st. The stock was sold at an average price of $479.99, for a total value of $10,079,790.00. Following the transaction, the chief financial officer directly owned 8,142 shares in the company, valued at approximately $3,908,078.58. This trade represents a 72.06% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which can be accessed through the SEC website.

James Edgemond also recently made the following trade(s):

• On Monday, November 24th, James Edgemond sold 21,000 shares of United Therapeutics stock. The shares were sold at an average price of $473.64, for a total value of $9,946,440.00.
• On Monday, November 17th, James Edgemond sold 21,000 shares of United Therapeutics stock. The shares were sold at an average price of $470.36, for a total value of $9,877,560.00.
• On Monday, November 10th, James Edgemond sold 21,000 shares of United Therapeutics stock. The stock was sold at an average price of $452.07, for a total value of $9,493,470.00.
• On Tuesday, November 4th, James Edgemond sold 21,000 shares of United Therapeutics stock. The stock was sold at an average price of $436.09, for a total value of $9,157,890.00.

United Therapeutics Trading Down 1.2%

NASDAQ UTHR traded down $5.81 during mid-day trading on Tuesday, hitting $474.14. The company’s stock had a trading volume of 308,992 shares, compared to its average volume of 584,417. The firm has a market capitalization of $20.42 billion, a price-to-earnings ratio of 17.97, a PEG ratio of 4.96 and a beta of 0.77. The company’s 50 day simple moving average is $448.96 and its 200 day simple moving average is $363.80. United Therapeutics Corporation has a twelve month low of $266.98 and a twelve month high of $492.62.

United Therapeutics (NASDAQ:UTHR) last released its quarterly earnings data on Wednesday, October 29th. The biotechnology company reported $7.16 earnings per share for the quarter, beating analysts’ consensus estimates of $6.89 by $0.27. The firm had revenue of $799.50 million for the quarter, compared to analyst estimates of $812.87 million. United Therapeutics had a net margin of 40.65% and a return on equity of 18.83%. The business’s quarterly revenue was up 6.8% compared to the same quarter last year. During the same period last year, the firm earned $6.39 earnings per share. As a group, research analysts forecast that United Therapeutics Corporation will post 24.48 EPS for the current year.

Analysts Set New Price Targets

Several equities analysts recently weighed in on UTHR shares. Jefferies Financial Group reaffirmed a “buy” rating and issued a $575.00 price target on shares of United Therapeutics in a research report on Wednesday, November 19th. Weiss Ratings reaffirmed a “buy (b-)” rating on shares of United Therapeutics in a research report on Monday. Oppenheimer upped their price target on United Therapeutics from $510.00 to $575.00 and gave the stock an “outperform” rating in a report on Friday, September 5th. Cantor Fitzgerald raised their price objective on United Therapeutics from $405.00 to $525.00 and gave the company an “overweight” rating in a research note on Wednesday, September 10th. Finally, Wells Fargo & Company lifted their price objective on shares of United Therapeutics from $414.00 to $423.00 and gave the stock an “equal weight” rating in a report on Thursday, October 30th. Eight investment analysts have rated the stock with a Buy rating and three have assigned a Hold rating to the company. Based on data from MarketBeat.com, the company has a consensus rating of “Moderate Buy” and a consensus target price of $505.00.

Hedge Funds Weigh In On United Therapeutics

A number of hedge funds and other institutional investors have recently made changes to their positions in UTHR. Darwin Global Management Ltd. purchased a new stake in United Therapeutics during the third quarter worth about $317,617,000. Norges Bank purchased a new position in United Therapeutics in the second quarter valued at about $136,453,000. Invesco Ltd. grew its position in shares of United Therapeutics by 90.2% during the 2nd quarter. Invesco Ltd. now owns 884,703 shares of the biotechnology company’s stock valued at $254,219,000 after acquiring an additional 419,588 shares during the period. AQR Capital Management LLC increased its stake in shares of United Therapeutics by 40.1% during the 2nd quarter. AQR Capital Management LLC now owns 1,273,161 shares of the biotechnology company’s stock worth $362,876,000 after purchasing an additional 364,713 shares during the last quarter. Finally, Nuveen LLC purchased a new stake in shares of United Therapeutics during the 1st quarter worth approximately $83,533,000. 94.08% of the stock is owned by hedge funds and other institutional investors.

United Therapeutics Company Profile

United Therapeutics Corporation, a biotechnology company, engages in the development and commercialization of products to address the unmet medical needs of patients with chronic and life-threatening diseases in the United States and internationally. The company offers Tyvaso DPI, an inhaled dry powder via pre-filled and single-use cartridges; Tyvaso, an inhaled solution via ultrasonic nebulizer; Remodulin (treprostinil) injection to treat patients with pulmonary arterial hypertension (PAH) to diminish symptoms associated with exercise; Orenitram, a tablet dosage form of treprostinil, to delay disease progression and improve exercise capacity in PAH patients; and Adcirca, an oral PDE-5 inhibitor to enhance the exercise ability in PAH patients.